Gallick G - Search Results

1

Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.

Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sen B, et al. Among authors: gallick g. Cancer Res. 2009 Mar 1;69(5):1958-65. doi: 10.1158/0008-5472.CAN-08-2944. Epub 2009 Feb 17. Cancer Res. 2009. PMID: 19223541 Free PMC article.

2

Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.

Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, Gallick GE. Boyd DD, et al. Clin Cancer Res. 2004 Feb 15;10(4):1545-55. doi: 10.1158/1078-0432.ccr-1565-02. Clin Cancer Res. 2004. PMID: 14977859

3

CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.

Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE. Cabioglu N, et al. Cancer Res. 2005 Aug 1;65(15):6493-7. doi: 10.1158/0008-5472.CAN-04-1303. Cancer Res. 2005. PMID: 16061624

4

SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.

Johnson FM, Gallick GE. Johnson FM, et al. Anticancer Agents Med Chem. 2007 Nov;7(6):651-9. doi: 10.2174/187152007784111278. Anticancer Agents Med Chem. 2007. PMID: 18045060 Review.

5

Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features.

Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Mandal M, et al. Cancer. 2008 May 1;112(9):2088-100. doi: 10.1002/cncr.23410. Cancer. 2008. PMID: 18327819 Free article.

6

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Kopetz S, et al. Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383922 Free PMC article.

7

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Varkaris A, et al. Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17. Int J Cancer. 2013. PMID: 23526299 Free PMC article.

8

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.

Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Kopetz S, et al. Among authors: gallick g. BMC Cancer. 2014 Sep 10;14:660. doi: 10.1186/1471-2407-14-660. BMC Cancer. 2014. PMID: 25208577 Free PMC article.

9

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Trevino JG, et al. Among authors: gallick ge. Am J Pathol. 2006 Mar;168(3):962-72. doi: 10.2353/ajpath.2006.050570. Am J Pathol. 2006. PMID: 16507911 Free PMC article.

10

Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.

Herynk MH, Zhang J, Parikh NU, Gallick GE. Herynk MH, et al. J Exp Ther Oncol. 2007;6(3):205-17. J Exp Ther Oncol. 2007. PMID: 17552361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters